Overview

Radiation-hormone and Docetaxel VS Radiation-hormone in Patients With High-Risk Localized Prostate Cancer

Status:
Active, not recruiting

Trial end date:
2023-11-14

Target enrollment:

Participant gender:

Summary

A prospective, multicenter, parallel-group, open-label, randomized, phase II Clinical Study of Radiation Therapy, Hormone Therapy and Docetaxel Versus Radiation Therapy and Hormone Therapy in Patients with High-Risk Localized Prostate Cancer (Stage III and IV) whose primary objective is determine the percentage of patients free of biochemical recurrence within 5 years of receiving a combination of radiation therapy with docetaxel associated with hormone therapy or the standard of care of radiation therapy and hormone therapy in patients with stage III and IV localized prostate cancer with a poor prognosis.

Phase:

Phase 2

Details

Lead Sponsor:

Spanish Oncology Genito-Urinary Group

Collaborator:

Pivotal S.L.

Treatments:

Docetaxel
Hormones